Analysts expect GE HealthCare to report Q3 2026 revenue of $5.04 billion and adjusted EPS of $1.21, with the current stock price of $93.12 trading below the average analyst price target of $102.50.
The primary focus for investors is the Adjusted EBIT Margin, which is expected to reflect the company's success in driving operational efficiencies and pricing power.
Recent performance has been supported by resilient demand in the Imaging and Ultrasound segments, although market participants remain cautious regarding the pace of healthcare capital equipment recovery in China. Investors will also be looking for updates on the integration of artificial intelligence across the company's product portfolio and any adjustments to the full-year 2026 financial outlook.